Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
01/06/20177:05AMGLOBEThe EndoPredict® Test Receives Positive Coverage Decisions from Multiple Blue Cross Blue Shield Affiliate Plans
SALT LAKE CITY, Jan. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced that multiple Blue Cross Blue Shield (BCBS) affiliate plans have issued positive coverage determinations for EndoPredict®, including Independence Blue Cross, Blue Cross and Blue... More...>>
01/05/20177:05AMGLOBEEndoPredict® Reviewed by Blue Cross Blue Shield Association’s Evidence Street
SALT LAKE CITY, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced that Evidence Street has reviewed EndoPredict®, Myriad’s second-generation test to predict breast cancer recurrence, and determined that the test results in a meaningful improvement... More...>>
12/28/20167:05AMGLOBEMyriad Genetics to Present at the 2017 JP Morgan Healthcare Conference
SALT LAKE CITY, Dec. 28, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2017 JP Morgan Healthcare Conference at 6:00 p.m. ET on January 9, 2017, at the Westin St. Francis Hotel in San Francisco, California... More...>>
12/27/20167:05AMGLOBEPositive Clinical Utility Results of Crescendo’s Vectra® DA Test for Rheumatoid Arthritis Published in the Journal Arthrit...
SALT LAKE CITY, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra® DA test to predict treatment response in patients with rheumatoid arthritis (RA) published online in the journal Arthritis &... More...>>
12/22/20162:03PMGLOBEUnited Rheumatology Issues Clinical Practice Guidelines and Recommends the Vectra® DA Test for Adults with Rheumatoid Arthri...
SALT LAKE CITY, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that United Rheumatology, a leading professional organization for rheumatologists in the United States with more that 300 members, has added Vectra® DA to its clinical... More...>>
12/09/20167:05AMGLOBEThe EndoPredict® Test Significantly Outperforms the First-Generation Test in Predicting the Risk of Node-Negative and Node-P...
SALT LAKE CITY, Dec. 09, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results of a large head-to-head study comparing the efficacy of six tests used to predict the recurrence of breast cancer.  A key finding was that EndoPredict®... More...>>
11/28/20167:05AMGLOBEMyriad Genetics Will Present Results from Six Breast Cancer Studies at SABCS
SALT LAKE CITY, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that the Company will present six breast cancer studies at the 2016 San Antonio Breast Cancer Symposium (SABCS) being held Dec. 6-10, 2016 in San Antonio, Texas... More...>>
11/12/20164:30PMGLOBECrescendo Bioscience Announces Four Studies with Vectra® DA Will Be Presented at the American College of Rheumatology 2016 A...
SALT LAKE CITY, Nov. 12, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that four poster presentations on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov. 11-16, 2016 in Washington, D.C.  ... More...>>
11/07/20167:05AMGLOBEMyriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx®
SALT LAKE CITY, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will submit its BRACAnalysis CDx® test for approval by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) in parallel with the PMDA review... More...>>
11/04/20167:05AMGLOBEThe GeneSight® Precision Medicine Test Drives Significant Medication Cost Savings in Patients with Generalized Anxiety Disor...
SALT LAKE CITY, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that a poster featuring the GeneSight® test will be presented at the Neuroscience Education Institute (NEI) Psychopharmacology Congress being held Nov. 3-6, 2016 in Colorado... More...>>
11/01/20164:05PMGLOBEMyriad Genetics Reports Fiscal First-Quarter 2017 Financial Results
Total Revenues of $177.5 MillionAdjusted EPS of $0.23 and Diluted EPS of ($0.02)Company Maintains Fiscal Year 2017 Financial Guidance and Issues Fiscal Second-Quarter 2017 Financial Guidance SALT LAKE CITY, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced financial results for its fiscal... More...>>
10/27/20167:05AMGLOBEThe Myriad myPath® Melanoma Test Effectively Diagnosed Patients in the Largest Outcomes-Based Study for a Melanoma Diagnosti...
SALT LAKE CITY, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present two new studies at the American Society of Dermatopathology (ASDP) annual meeting being held Oct. 27-30, 2016 in Chicago, Ill.  The research... More...>>
10/26/20167:15AMGLOBEMyriad’s BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Tre...
SALT LAKE CITY, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDx®  test accurately identified patients who may benefit from treatment with olaparib.  The BRACAnalysis CDx test was included... More...>>
10/25/20167:05AMGLOBEMyriad RBM Announces an Agreement with Sanofi to Measure Predictive Cardiovascular Biomarkers in Patients with Diabetes
SALT LAKE CITY, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that it will work with Sanofi, a global and diversified healthcare leader, to perform a biomarker analysis of blood samples from the Evaluation of Lixisenatide in Acute Coronary... More...>>
10/21/20169:29AMGLOBEMyriad Genetics Inc. Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services to the Nat...
SALT LAKE CITY, Oct. 21, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, and ION Solutions, a part of AmerisourceBergen, and the largest physician services organization specializing in the support of community oncology, announced today that they have entered into... More...>>
10/20/20167:05AMGLOBEMyriad to Announce Fiscal First-Quarter 2017 Financial Results on November 1
SALT LAKE CITY, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal first-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, November 1, 2016.  During the call, Mark C. Capone, president and CEO and... More...>>
10/18/20167:05AMGLOBEMyriad Genetics Teams Up with Project BioEYES to Advance STEM Education in Utah
SALT LAKE CITY, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that more than 40 of its employees are volunteering to support Project BioEYES, which is a science, technology, engineering and math (STEM) education program... More...>>
10/17/20167:05AMGLOBEMyriad Will Present New Data on Its Variant Classification Program at the ASHG Annual Meeting
SALT LAKE CITY, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present four new studies at the American Society of Human Genetics Annual Meeting being held Oct. 18-22, 2016 in Vancouver, British Columbia. The research... More...>>
10/08/20162:30AMONEMyriad's myChoice® HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib
SALT LAKE CITY, Oct. 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its myChoice® HRD test identified more than double the number of patients who may benefit from treatment with niraparib than were identified by germline BRCA testing... More...>>
10/08/20162:30AMGLOBEMyriad’s myChoice® HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib
SALT LAKE CITY, Oct. 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its myChoice® HRD test identified more than double the number of patients who may benefit from treatment with niraparib than were identified by germline... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20170118 01:45:09